Teva Launches Generic EpiPen At Same Price As Mylan's Generic
Teva's epinephrine will be the first alternative to branded and authorized generics made by Mylan, but the wholesale acquisition cost of $300 for a two-pack won't be lower.
You may also be interested in...
Teva secretly conspired with Mylan and Pfizer to delay generic versions of one another’s lucrative brands by several years, a newly-filed US antitrust lawsuit naming the Israeli firm alleges.
Mylan has blamed a sluggish uptake for its Copaxone rival and a delay in FDA approval of its generic version of Advair Diskus for the firm’s sales suffering a 4% drop and EBITDA falling by 8% in 2018.
Two-and-a-half years after receiving a complete response letter, Teva's ANDA clears FDA; agency issued three guidances for development of generic epinephrine auto-injectors.